Abstract: The invention generally relates to a pipeline leak detection system. The system, comprising at least one fluid collection member adapted to be placed adjacent a pipeline and adapted to receive fluid leaking from the pipeline; a flexible cover covering at feast part of the pipeline and the at least one fluid collection member; and a fluid detector in fluid communication with the at least one fluid collection member.

Abstract: Antagonists of group 1 metabotropic glutamate receptors (mGluR) potentiate the effect of positive AMPA receptor modulators on neurotrophin expression, such as brain-derived neurotrophic factor (BDNF). The findings described herein suggest a combinatorial approach for drug therapies, using both positive AMPA receptor modulators and mGluR antagonists, to enhance brain neurotrophism.

Abstract: Antagonists of group 1 metabotropic glutamate receptors (mGluR) potentiate the effect of positive AMPA receptor modulators on neurotrophin expression, such as brain-derived neurotrophic factor (BDNF). The findings described herein suggest a combinatorial approach for drug therapies, using both positive AMPA receptor modulators and mGluR antagonists, to enhance brain neurotrophism.

Abstract: The present invention provides methods of increasing sexual arousal and performance behaviors in female mammals by administration of a therapeutically acceptable amount of a positive modulator of an AMPA-type glutamate receptor.

Abstract: Antagonists of group 1 metabotropic glutamate receptors (mGluR) potentiate the effect of positive AMPA receptor modulators on neurotrophin expression, such as brain-derived neurotrophic factor (BDNF). The findings described herein suggest a combinatorial approach for drug therapies, using both positive AMPA receptor modulators and mGluR antagonists. to enhance brain neurotrophism.

Abstract: This invention provides novel methods of treatment to ameliorate or prevent cognitive disorder/dysfunction in pre- or asymptomatic subject having one or more mutations in the Huntington gene. The methods involve increasing the expression or activity of the neurotrophin BDNS in the brain of said subject.

Abstract: This invention provides methods of preserving, improving, or restoring cognitive function in mammal having one or more mutations in the FMR1 gene (e.g. at risk for or having fragile x syndrome), where the methods involve the brain derived neurotrophic factor (BDNF) level or activity in the brain of said mammal. In certain embodiments the methods involve administering one or more AMPA potentiators (e.g., ampakines) to the mammal in an amount sufficient to increase BDNF levels in the brain of the mammal.

Abstract: The present invention provides brain cells, such as normal brain cells, apolipoprotein E deficient brain cells, or apoE4 containing brain cells, that are treated with a compound which can modulate integrins and/or integrin receptors to produce increased sequestration of and/or accumulation of and/or uptake of A?, and/or changes in cathepsin D content and/or lysosomal dysfunction, and/or microglia activation in the brain cells. The present invention also provides methods for producing such cells and methods for using the cells for screening an agent or substance that modulates the sequestration of and/or accumulation of and/or uptake of A?, and/or lysosomal dysfunction, and/or changes in cathepsin D content and/or microglia activation in the brain cells. The method further provides a new therapeutic target, antagonism of glutamate receptors, for the treatment of neurodegenerative diseases which are characterized by inter alia, abnormal amyloid uptake and/or accumulation.

Abstract: This invention relates to methods and devices for the detection and characterization of psychoactive compounds by analyzing alterations of network level physiological characteristics before and after the introduction of a candidate sample onto an in vitro neuronal tissue sample. The invention further provides a software package that enables an operator to deliver a timed electrical pulse to neuronal samples at a specific point in their spontaneous or induced oscillations. Such temporal stimulations trigger unexpected and useful network level physiological responses.

Abstract: The present invention provides brain cells, such as normal brain cells, apolipoprotein E deficient brain cells, or apoE4 containing brain cells, that are treated with a compound which can modulate integrins and/or integrin receptors to produce increased sequestration of and/or accumulation of and/or uptake of A?, and/or changes in cathepsin D content and/or lysosomal dysfunction, and/or microglia activation in the brain cells. The present invention also provides methods for producing such cells and methods for using the cells for screening an agent or substance that modulates the sequestration of and/or accumulation of and/or uptake of A?, and/or lysosomal dysfunction, and/or changes in cathepsin D content and/or microglia activation in the brain cells. The method further provides a new therapeutic target, antagonism of glutamate receptors, for the treatment of neurodegenerative diseases which are characterized by inter alia, abnormal amyloid uptake and/or accumulation.

Abstract: This invention relates to methods of use for AMPA receptor potentiator compounds and pharmaceutical compositions in the prevention and treatment of cognitive impairment as a result of acute or chronic sleep deprivation, including enhancement of receptor functioning at synapses in brain networks responsible for higher order behaviors. A still further aspect of the present invention is the use of an active agent as described above for the preparation of a medicament for the treatment of a disorder as described above.

Abstract: The present invention relates to () non-peptide aspartyl protease inhibitors; (ii) methods for modulating the processing of an amyloid precursor protein (APP); (iii) methods for modulating the processing of a tau protein (?-protein); and (iv) methods for treating neurodegenerative diseases.

Abstract: Ethernet and Universal Serial Bus (USB) powered printing devices are provided. In particular, Ethernet and USB powered printers and methods of Ethernet powering of printers that support high speed printing and/or data intensive printing. Such high-speed and/or data intensive printing operations are able to be Ethernet or USB powered by providing for a power storage unit within the printer device that is able be charged during non-printing periods and provide for necessary energy bursts to support such higher powered processes. In addition, the present invention provides for devices and methods that allow for printers to operate with main power provided by conventional power mains and for back-up or secondary power to be supplied by Ethernet or USB power. Additionally, the invention provides for Ethernet or USB powering, both primary and back-up, of the data and configuration settings in the printer control and image generating electronics.

Abstract: The present invention relates to a method for enhancing the physiological and therapeutic effects of an AMPA receptor potentiator in an animal by co-administration of an acetylcholinesterase inhibitor with the potentiator. Also disclosed is a method for treating a cognitive disorder in an animal by co-administration of an AMPA receptor potentiator and an acetylcholinesterase inhibitor. In addition, a composition comprising an effective amount of an AMPA receptor potentiator and an effective amount of an acetylcholinesterase inhibitor is also disclosed.

Abstract: The present invention provides a model for studying the development of, and/or pathologies associated with neurodegenerative diseases, and agents that can alter such development and/or pathologies. The model of the invention is especially useful as an Alzheimer's disease model. The model of the invention provides brain cells and a method for increasing neurodegenerative disease characteristics in such cells, especially, induction of neurofibrillary tangles and/or phosphorylated tau and/or tau fragments and/or the production and/or release of cytokines and/or microglia reactions and/or activations and/or inflammation and/or conversion of p35 to p25 and/or the levels and activities of protein kinases by selectively increasing the concentration of cathepsin D to an effective level, and/or by lowering the concentration of cholesterol in such cells.

Abstract: The present invention provides a model for studying the development of, and/or pathologies associated with neurodegenerative diseases, and agents that can alter such development and/or pathologies. The model of the invention is especially useful as an Alzheimer's disease model. The model of the invention provides brain cells and a method for increasing neurodegenerative disease characteristics in such cells, especially, induction of neurofibrillary tangles and/or phosphorylated tau and/or tau fragments and/or the production and/or release of cytokines and/or microglia reactions and/or activations and/or inflammation and/or conversion of p35 to p25 and/or the levels and activities of protein kinases by selectively increasing the concentration of cathepsin D to an effective level, and/or by lowering the concentration of cholesterol in such cells.

Abstract: The present invention relates to (i) non-peptide aspartyl protease inhibitors; (ii) methods for modulating the processing of an amyloid precursor protein (APP); (iii) methods for modulating the processing of a tau protein (&tgr;-protein); and (iv) methods for treating neurodegenerative diseases.

Abstract: This invention relates to methods for the detection and characterization of psychoactives in neuronal tissue by comparing parameters measured for a set of baseline oscillations with those same parameters measured for a set of resulting oscillations. The baseline oscillations are induced or stimulated by such agents as chemical compounds that effect cholinergic interactions, co-deposited neuronal tissue, or electrical stimulations. The resulting set of oscillations is obtained after exposing the neuronal tissue to a sample composition that may or may not contain a psychoactive. By comparing the parameters for the baseline and resulting oscillations, the psychoactive in the sample composition may be detected and characterized as belonging to a specific psychoactive compound class and in some instances, may be distinguished from other members of the psychoactive compound class.

Abstract: Methods for modulating the endocrine system of a mammal are provided. In the subject methods, a positive allosteric modulator of AMPA receptors of the hypothalamus are administered to the host. The subject methods find use in applications where it is desired to increase the circulatory level of a hormone in a mammalian host, such as diseased states characterized by abnormally depressed circulatory levels of the hormone.

Abstract: Methods are provided for inhibiting cell adhesion molecule cleavage in brain tissue of a host. In the subject methods, an effective amount of a protease inhibitor, particularly serine protease inhibitors, such as those that inhibit tPA and related proteases, is administered to the host. The subject methods find use in the treatment and prevention of pathophysiology and neuropathology in a host, such as the treatment of a variety of pathological conditions resulting from pathophysiology and/or excitotoxicity. Specific pathological conditions in which the subject methods find use include epilepsy (and related seizure states) and neuronal damage associated with excessive glutamate activity, e.g. resulting from an acute event such as hypoxia, head trauma or stroke.